1
|
Khor CS, Tsuji R, Lee HY, Nor’e SS, Sahimin N, Azman AS, Tiong V, Hasandarvish P, Teoh BT, Soh YH, Chai JH, Kokubo T, Kanauchi O, Yamamoto N, AbuBakar S. Lactococcus lactis Strain Plasma Intake Suppresses the Incidence of Dengue Fever-like Symptoms in Healthy Malaysians: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2021; 13:nu13124507. [PMID: 34960061 PMCID: PMC8707015 DOI: 10.3390/nu13124507] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 12/09/2021] [Accepted: 12/10/2021] [Indexed: 12/31/2022] Open
Abstract
Dengue fever (DF) is a mosquito-borne disease still with no effective treatment or vaccine available. A randomized, placebo-controlled, double-blinded, parallel-group trial was undertaken to evaluate the efficacy of oral intake of Lactococcus lactis strain plasma (LC-Plasma) on the presentation and severity of DF-like symptoms among healthy volunteers. Study participants (320) were assigned into two groups, and consumed either placebo or LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks. The clinical symptoms of DF were self-recorded through questionnaires, and exposure to DENV was determined by serum antibody and/or DENV antigen tests. No significant differences between groups were observed for exposure to DENV, or the symptomatic ratio. Results obtained showed that participants from the LC-Plasma group reported a significant reduction in the cumulative incidence days of DF-like symptoms, which include fever (p < 0.001), muscle pain (p < 0.005), joint pain (p < 0.001), and pain behind the eyes (p < 0.001), compared to that of the placebo group. Subgroup analysis revealed a significantly (p < 0.05) reduced severity score in the LC-Plasma group when study sites were separately analyzed. Overall, our findings suggest that LC-Plasma supplementation reduces the cumulative days with DF-like symptoms, and the severity of the symptoms. Daily oral intake of LC-Plasma, hence, is shown to mitigate the DF-like symptoms.
Collapse
Affiliation(s)
- Chee-Sieng Khor
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Ryohei Tsuji
- Kirin Central Research Institute, Kirin Holdings Co., Ltd., Yokohama 236-0004, Japan; (R.T.); (T.K.)
| | - Hai-Yen Lee
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Siti-Sarah Nor’e
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Norhidayu Sahimin
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Adzzie-Shazleen Azman
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Vunjia Tiong
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Pouya Hasandarvish
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Boon-Teong Teoh
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Yih-Harng Soh
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Jian-Hai Chai
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
| | - Takeshi Kokubo
- Kirin Central Research Institute, Kirin Holdings Co., Ltd., Yokohama 236-0004, Japan; (R.T.); (T.K.)
| | - Osamu Kanauchi
- Research and Development Strategy Department, Kirin Holdings Co., Ltd., Tokyo 164-0001, Japan;
| | - Naoki Yamamoto
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Chiba 272-8516, Japan;
- Tokyo Medical and Dental University, Tokyo 113-8519, Japan
| | - Sazaly AbuBakar
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia; (C.-S.K.); (H.-Y.L.); (S.-S.N.); (N.S.); (A.-S.A.); (V.T.); (P.H.); (B.-T.T.); (Y.-H.S.); (J.-H.C.)
- Correspondence:
| |
Collapse
|
2
|
Zahedifard M, Faraj FL, Paydar M, Looi CY, Hasandarvish P, Hajrezaie M, Kamalidehghan B, Majid NA, Khalifa SAM, Ali HM, Abdulla MA, El-Seedi HR. Synthesis of Apoptotic New Quinazolinone-Based Compound and Identification of its Underlying Mitochondrial Signalling Pathway in Breast Cancer Cells. Curr Pharm Des 2016; 21:3417-26. [PMID: 25808938 DOI: 10.2174/1381612821666150326104952] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 03/19/2015] [Indexed: 11/22/2022]
Abstract
The anti-carcinogenic effect of the new quinazolinone compound, named MMD, was tested on MCF-7 human breast cancer cell line. The synthesis of quinazolinone-based compounds attracted strong attention over the past few decades as an alternative mean to produce analogues of natural products. Quinazolinone compounds sharing the main principal core structures are currently introduced in the clinical trials and pharmaceutical markets as anti-cancer agents. Thus, it is of high clinical interest to identify a new drug that could be used to control the growth and expansion of cancer cells. Quinazolinone is a metabolite derivative resulting from the conjugation of 2-aminobenzoyhydrazide and 5-methoxy-2- hydroxybenzaldehyde based on condensation reactions. In the present study, we analysed the influence of MMD on breast cancer adenoma cell morphology, cell cycle arrest, DNA fragmentation, cytochrome c release and caspases activity. MCF-7 is a type of cell line representing the breast cancer adenoma cells that can be expanded and differentiated in culture. Using different in vitro strategies and specific antibodies, we demonstrate a novel role for MMD in the inhibition of cell proliferation and initiation of the programmed cell death. MMD was found to increase cytochrome c release from the mitochondria to the cytosol and this effect was enhanced over time with effective IC50 value of 5.85 ± 0.71 μg/mL detected in a 72-hours treatment. Additionally, MMD induced cell cycle arrest at G0/G1 phase and caused DNA fragmentation with obvious activation of caspase-9 and caspases-3/7. Our results demonstrate a novel role of MMD as an anti-proliferative agent and imply the involvement of mitochondrial intrinsic pathway in the observed apoptosis.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Hesham R El-Seedi
- Department of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia, Department of Experimental Hematology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden; Division of Pharmacognosy, Department of Medicinal Chemistry, Uppsala University, Box 574, SE-75 123, Uppsala, Sweden.
| |
Collapse
|